Bharat Biotech announces phase 3 results of Covaxin, says it demonstrates interim clinical efficacy of 81%

Bharat Biotech has announced the results of phase 3 clinical trials of its Covid-19 vaccine candidate Covaxin. India's first Covid vaccine has demonstrated interim clinical efficacy of 81 per cent.

The phase 3 study of Covaxin involved 25,800 participants between 18-98 years of age.